• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

4-Antibody AG, Jena

4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating fulllength IgG format human antibody libraries expressed in mammalian B cells. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an inhouse pipeline of antibody drugs. The Company's lead development product is an anticytomegalovirus antibody drug. 4-Antibody is a private company with strong, commerciallyexperienced leadership located in Basel, Switzerland and Jena, Germany. *

 

	Start	2010-11-06 existent
	Group	4-Antibody (Group)
	Industry	therapeutic antibody
	Region	Jena
	Country	Germany
	Street	2 Winzerlaer Str.
	City	07745 Jena
	Tel	+49-3641-508-230
	Fax	+49-3641-508-113
		Address record changed: 2011-04-15
Basic data	Employees	B: 11 to 50 (2008-10-01)
		* Document for »About Section«: 4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel.
		Record changed: 2011-11-25

Advertisement

More documents for 4-Antibody (Group)

• [1] 4-Antibody AG. (1/29/13). "Press Release: 4-Antibody AG and the Ludwig Institute Expand Oncology Antibody R&D Program with Three New Targets". Basel & New York, NY....
• [2] 4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel....
• [3] Evotec AG. (5/9/12). "Press Release: Evotec AG and 4-Antibody AG Form Strategic Collaboration to Innovate Antibody Selection. Evotec and 4-Antibody Launch New High Content Screening Platform for Early Antibody Functionality Testing". Hamburg & Basel....
• [4] 4-Antibody AG. (9/19/11). "Press Release: 4-Antibody AG Meets Next Milestone in Boehringer Ingelheim Collaboration". Basel....
• [5] 4-Antibody AG. (8/16/11). "Press Release: 4-Antibody AG Forms Collaboration with Human Genome Sciences". Basel....
• [6] 4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel....
• [7] 4-Antibody AG. (9/21/09). "Press Release: 4-Antibody Received Notice of Allowance for U.S. Patent Application Describing the Hu-PAC Technology". Basel....
• [8] 4-Antibody AG. (9/11/09). "Press Release: Retrocyte Display Technology Patent Applications Published". Basel....
• [9] Pharming Group N.V.. (10/13/08). "Press Release: Pharming Shareholders Appoint Sijmen de Vries as new CEO". Leiden....
• [10] 4-Antibody AG. (9/26/08). "Press Release: 4-Antibody Appoints Dr. Richard Mason as New Chief Executive Officer". Basel....

To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to info@iito.de and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2013. Made in Germany.